AllAnalyst Report
logoMorningstarOctober 30, 2020

Intercept Pharmaceuticals, Inc.: Placing Intercept Pharmaceuticals Under Review

Symbols
ICPT
Sector(s)
Healthcare
Rating
Current Price
$18.15
Fair Value
Economic Moat
Stewardship
Summary

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free

Analyst Profile

Anna Baran

Equity Analyst
Anna Baran is an equity analyst on the healthcare team for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc.Before joining Morningstar in 2016, Baran completed a research project in oncology at the Feinberg School of Medicine and another research thesis in neurobiology at Northwestern University. Before moving to her current role in February 2018, she was on the global and managed portfolios service teams at Morningstar.Baran holds a bachelor’s degree in economics and biological sciences from Northwestern University. She is also a Level II candidate in the Chartered Financial Analyst® program.